New York State Common Retirement Fund purchased a new stake in shares of Aquestive Therapeutics Inc (NASDAQ:AQST) in the fourth quarter, Holdings Channel reports. The firm purchased 4,500 shares of the company’s stock, valued at approximately $28,000.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its position in Aquestive Therapeutics by 245,514.3% during the 4th quarter. Bank of Montreal Can now owns 120,351 shares of the company’s stock worth $758,000 after acquiring an additional 120,302 shares during the period. Vanguard Group Inc acquired a new stake in Aquestive Therapeutics during the 3rd quarter worth about $8,055,000. Vanguard Group Inc. acquired a new stake in Aquestive Therapeutics during the 3rd quarter worth about $8,055,000. Point72 Asset Management L.P. acquired a new stake in Aquestive Therapeutics during the 3rd quarter worth about $350,000. Finally, Crestline Management LP acquired a new stake in Aquestive Therapeutics during the 3rd quarter worth about $201,422,000. Institutional investors and hedge funds own 66.01% of the company’s stock.

A number of brokerages have commented on AQST. Zacks Investment Research lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 24th. Wedbush restated a “buy” rating and set a $30.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, December 14th. Finally, Lake Street Capital began coverage on Aquestive Therapeutics in a research report on Thursday, January 3rd. They set a “buy” rating and a $14.00 price objective for the company. Six research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $20.96.

Shares of Aquestive Therapeutics stock opened at $6.31 on Wednesday. The stock has a market cap of $166.86 million and a PE ratio of -2.25. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.25 and a quick ratio of 2.09. Aquestive Therapeutics Inc has a 52-week low of $5.60 and a 52-week high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.35. The firm had revenue of $16.82 million for the quarter, compared to analyst estimates of $17.05 million. Equities analysts expect that Aquestive Therapeutics Inc will post -1.91 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dailypolitical.com/2019/04/10/new-york-state-common-retirement-fund-invests-28000-in-aquestive-therapeutics-inc-aqst-stock.html.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Further Reading: Dividend

Want to see what other hedge funds are holding AQST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquestive Therapeutics Inc (NASDAQ:AQST).

Institutional Ownership by Quarter for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.